Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations study found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://benniftsofproleviate89020.blogrenanda.com/45679441/conolidin-to-replace-traditional-painkillers-fundamentals-explained